Callosum
Software infrastructure allowing AI workloads to run across different chips and models
$100MSeed
Role not disclosedActivity from announced rounds
DCVC is an investment firm identified by TypeSafe AI as an existing investor and by its own communications as a backer of Shennon Biotechnologies.
TypeSafe turns unstructured inputs into typed decisions and probability scores for automated software. Shennon develops T-cell engager therapies for solid tumors. Separate TypeSafe financings remain separate events under one investor history.